Equinix, Inc. is a global digital infrastructure company. Equinix combines a global footprint of International Business Exchange or IBX data centers, interconnection solutions and edge services for deploying network. It includes unique business, digital ecosystems, and expert consulting and support. The company has 3 reportable segments comprised of the Americas, Middle East and Africa and Asia-Pacific geographic regions. It has a direct sales force and a channel marketing program. Its business is based on a recurring revenue model comprising colocation, related interconnection and managed IT infrastructure services. These services are considered to be recurring, as customers are billed at fixed rates on a recurring basis through the life of the respective contracts. Non-recurring revenues comprise installation services related to initial deployment and professional services. Also, revenues from customer settlements (fees paid for terminating contracts before expiry) are treated as contract modifications....
+See More2020-02-02 10:31:00 Sunday ET
Our proprietary alpha investment model outperforms the major stock market benchmarks such as S&P 500, MSCI, Dow Jones, and Nasdaq. We implement
2018-04-13 14:42:00 Friday ET
Mike Pompeo switches his critical role from CIA Director to State Secretary in a secret visit to North Korea with no regime change as the North Korean dicta
2019-04-01 08:28:00 Monday ET
OraSure and its subsidiary DNA Genotek specialize in the lean production of home DNA spit tubes. OraSure extracts core genetic information from microbiome s
2018-10-09 08:40:00 Tuesday ET
The International Monetary Fund (IMF) appoints Harvard professor Gita Gopinath as its chief economist. Gopinath follows her PhD advisor and trailblazer Kenn
2018-01-10 08:40:00 Wednesday ET
President Trump considers imposing retaliatory economic sanctions on Chinese products and services in direct response to China's theft and infringement
2019-01-10 17:31:00 Thursday ET
The recent Bristol-Myers Squibb acquisition of American Celgene is the $90 billion biggest biotech deal in history. The resultant biopharma goliath would be